References
1. Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia 2021;76:655-64.
2. Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene–a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364-73.
3. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-9.
4. Podranski T, Bouillon T, Schumacher PM, et al. Compartmental pharmacokinetics of dantrolene in adults: do malignant hyperthermia association dosing guidelines work? Anesth Analg 2005;101:1695-9.
5. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007;24:2187-97.
6. Lerman J, McLeod ME, Strong HA. Pharmacokinetics of intravenous dantrolene in children. Anesthesiology 1989;70:625-9.
7. Schenk MR, Beck DH, Nolte M, et al. Continuous veno-venous hemofiltration for the immediate management of massive rhabdomyolysis after fulminant malignant hyperthermia in a bodybuilder. Anesthesiology 2001;94:1139-41.
Table1 Pharmacokinetic parameters estimated for dantrolene. (A) during PE period, (B) during CVVH and PE period, (C) after PE, only with renal clearance, (D) the whole course as (B)+(C)